US 2017/0281682 A1Published application

Chimeric receptors and uses thereof in immune therapy

AssigneeUnum Therapeutics Inc.

InventorsCharles Wilson, Kathleen McGinness

Life of this patent

Estimating the term…

Loading patent…

Abstract

Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig), an Fc-binding domain; a transmembrane domain; at least one co-stimulatory signaling domain; and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.

Claims72

Dependent claims

A chimeric receptor, comprising:

(a) an Fc binding domain;
(b) a transmembrane domain;
(c) at least one co-stimulatory signaling domain;
and
(d) a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM);
wherein either (c) or (d) is located at the C-terminus of the chimeric receptor;
and wherein
(i) if (a) is an extracellular ligand-binding domain of CD16A, (d) does not comprise an ITAM domain of an Fc receptor, and
(ii) the chimeric receptor is not a receptor comprising, from N-terminus to C-terminus, an extracellular ligand-binding domain of F158 CD16A or V158 CD16A, a hinge and transmembrane domain of CD8a, a co-stimulatory signaling domain of 4-1BB, and a cytoplasmic signaling domain of CD3ζ.

6 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/509,133Filed 9 Sep 2015
Priority: 9 Sep 2014
Published: 5 Oct 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification31 codes

C07K 14/70535
Immunoglobulin superfamily: fc-receptors, e.g. CD16, CD32, CD64
A61K 39/395
Medicinal preparations containing antigens or antibodies: antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]

Family

Application62/047,916Us provisional application · filed 9 Sep 2014
US 2018/0133252 A9Published application
US 2017/0281682 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key